NASDAQ$AMGN
Amgen Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Amgen reported a 7% increase in total revenue, driven by higher volume growth, but faced a decrease in GAAP EPS due to amortization of costs associated with the Otezla acquisition.
Amgen's Q4 2020 financial results showed a 7% increase in total revenues to $6.6 billion, driven by volume growth. However, GAAP EPS decreased by 3% to $2.76, primarily due to Otezla acquisition costs. Non-GAAP EPS increased by 5% to $3.81. The company's 2021 revenue guidance is $25.8-$26.6 billion.
- Total revenues increased by 7% to $6.6 billion, driven by higher volume growth.
- GAAP EPS decreased by 3% to $2.76, impacted by Otezla acquisition amortization.
- Non-GAAP EPS increased by 5% to $3.81, driven by increased revenues.
- Product sales increased 8% globally, driven by 13% volume growth across the portfolio.
Headline financials
Revenue & EPS history
Amgen · Revenue · Quarterly
$6.63B
Revenue by segment
Amgen · $5.85B total across 16 segments · Q4 2020
- Enbrel$1.27B-5.5%21.8%
- Prolia$749M-0.4%12.8%
- Otezla$617M+246.6%10.6%
- Neulasta$536M-19.4%9.2%
- XGEVA$502M+2.7%8.6%
- Aranesp$375M-12.2%6.4%
- MVASI$280M+233.3%4.8%
- KYPROLIS$272M+2.3%4.7%
- Repatha$253M+26.5%4.3%
- Nplate$227M+8.1%3.9%
- Vectibix$221M+21.4%3.8%
- Parsabiv$172M-3.9%2.9%
- AMJEVITA/AMGEVITA$103M+45.1%1.8%
- BLINCYTO$103M+28.7%1.8%
- EVENITY$90M+5.9%1.5%
- Other products$76M-12.6%1.3%
Forward guidance
Amgen anticipates total revenues between $25.8 billion and $26.6 billion for 2021. The company projects GAAP EPS to be in the range of $12.12 to $13.17 and non-GAAP EPS in the range of $16.00 to $17.00.
Tailwinds
- Total revenues in the range of $25.8 billion to $26.6 billion.
- GAAP EPS in the range of $12.12 to $13.17.
- Non-GAAP EPS in the range of $16.00 to $17.00.
- Capital expenditures to be approximately $900 million.
- Share repurchases in the range of $3.0B to $4.0B subject to our Board's authorization.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2020
+0.3%
Avg return
Earnings day
+0.0%
Avg return
5 days after
+0.1%
Avg return
30 days after
53%
39 / 73 earnings
Positive
+12.2%
Q1 2024
Best reaction
-8.7%
Q3 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.9% | -4.4% | -2.7% | |
| Q4 2025 | +3.0% | +11.0% | +9.1% | |
| Q3 2025 | +7.7% | +9.1% | +11.2% | |
| Q2 2025 | -5.1% | -5.0% | -5.5% | |
| Q1 2025 | -1.1% | -2.8% | +1.6% | |
| Q4 2024 | +6.5% | +2.0% | +12.4% | |
| Q3 2024 | +1.3% | +0.3% | -10.5% | |
| Q2 2024 | -3.9% | -0.8% | -0.3% | |
| Q1 2024 | +12.2% | +8.3% | +10.3% | |
| Q4 2023 | -8.1% | -9.6% | -15.3% | |
| Q3 2023 | -0.9% | +2.5% | +2.5% | |
| Q2 2023 | +5.6% | +13.2% | +11.4% | |
| Q1 2023 | +0.4% | -1.2% | -9.2% | |
| Q4 2022 | -2.1% | -2.6% | -6.7% | |
| Q3 2022 | +0.0% | +8.7% | +6.1% | |
| Q2 2022 | -0.4% | +0.5% | -1.9% | |
| Q1 2022 | -4.7% | -7.6% | +2.2% | |
| Q4 2021 | +8.5% | +2.7% | +4.2% | |
| Q3 2021 | +4.0% | +1.9% | -4.1% | |
| Q2 2021 | -4.8% | -4.0% | -5.8% | |
| Q1 2021 | -7.4% | -6.2% | -7.9% | |
| Q4 2020 | -1.4% | -1.7% | -7.7% | |
| Q3 2020 | -2.5% | -1.5% | +0.6% | |
| Q2 2020 | -1.9% | -3.5% | -0.3% | |
| Q1 2020 | -2.0% | +0.3% | -2.5% | |
| Q4 2019 | -4.9% | -2.4% | -12.1% | |
| Q3 2019 | +2.9% | +6.3% | +14.4% | |
| Q2 2019 | +6.0% | +6.3% | +17.5% | |
| Q1 2019 | -2.8% | -2.1% | -6.7% | |
| Q4 2018 | -3.7% | -2.5% | -1.0% | |
| Q3 2018 | +2.4% | -0.6% | +7.5% | |
| Q2 2018 | -0.3% | +1.8% | +1.9% | |
| Q1 2018 | +0.1% | +1.6% | +1.9% | |
| Q4 2017 | +0.5% | -5.1% | -0.5% | |
| Q3 2017 | -2.1% | -3.2% | -5.7% | |
| Q2 2017 | -2.9% | -3.6% | -6.1% | |
| Q1 2017 | -1.2% | -1.3% | -5.9% | |
| Q4 2016 | +4.9% | +4.5% | +12.9% | |
| Q3 2016 | -8.7% | -11.5% | -8.5% | |
| Q2 2016 | +2.2% | +3.9% | +2.6% | |
| Q1 2016 | -1.7% | — | — | |
| Q4 2015 | +1.5% | — | — | |
| Q3 2015 | -0.9% | — | — | |
| Q2 2015 | +3.0% | — | — | |
| Q1 2015 | +1.9% | — | — | |
| Q4 2014 | -3.2% | — | — | |
| Q3 2014 | +6.7% | — | — | |
| Q2 2014 | +6.0% | — | — | |
| Q1 2014 | -3.2% | — | — | |
| Q4 2013 | +0.5% | — | — | |
| Q3 2013 | +1.8% | — | — | |
| Q2 2013 | -1.0% | — | — | |
| Q1 2013 | -7.5% | — | — | |
| Q4 2012 | -0.8% | — | — | |
| Q3 2012 | +0.8% | — | — | |
| Q2 2012 | +7.6% | — | — | |
| Q1 2012 | +0.2% | — | — | |
| Q4 2011 | -0.8% | — | — | |
| Q3 2011 | +4.9% | — | — | |
| Q2 2011 | -3.0% | — | — | |
| Q1 2011 | -1.5% | — | — | |
| Q4 2007 | +0.7% | — | — | |
| Q4 2010 | +0.7% | — | — | |
| Q3 2008 | +0.7% | — | — | |
| Q3 2010 | -0.9% | — | — | |
| Q2 2010 | -0.4% | — | — | |
| Q1 2009 | +1.5% | — | — | |
| Q1 2010 | +1.2% | — | — | |
| Q4 2009 | +0.5% | — | — | |
| Q3 2009 | +1.6% | — | — | |
| Q4 2008 | +3.8% | — | — | |
| Q2 2009 | +3.8% | — | — | |
| Q2 2008 | +3.8% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro